Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (CheckMate 568)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02659059
Recruitment Status : Active, not recruiting
First Posted : January 20, 2016
Last Update Posted : July 12, 2019
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb

Brief Summary:

The purpose of part 1 of this study is to determine the objective response rate (ORR) in stage IV NSCLC subjects treated with nivolumab in combination with ipilimumab as first line therapy.

The purpose of part 2 of this study is to determine the safety and tolerability of nivolumab and ipilimumab combined with a short course of chemotherapy in first line stage IV NSCLC.


Condition or disease Intervention/treatment Phase
Non-Small-Cell Lung Cancer Biological: Nivolumab Biological: Ipilimumab Drug: Carboplatin Drug: Cisplatin Drug: Paclitaxel Drug: Pemetrexed Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 506 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Study of Nivolumab in Combination With Ipilimumab (Part 1); and Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)
Actual Study Start Date : February 10, 2016
Actual Primary Completion Date : June 22, 2018
Estimated Study Completion Date : April 20, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Nivolumab+Ipilimumab

Part 1

Specified Dose on Specified Days

Biological: Nivolumab
Specified Dose on Specified Days
Other Names:
  • BMS-936558
  • Opdivo

Biological: Ipilimumab
Specified Dose on Specified Days
Other Names:
  • BMS-734016
  • Yervoy

Experimental: Nivolumab+Ipilimumab + 2 cycles Platinum Doublet Chemotherapy

Part 2

Specified Dose on Specified Days

Biological: Nivolumab
Specified Dose on Specified Days
Other Names:
  • BMS-936558
  • Opdivo

Biological: Ipilimumab
Specified Dose on Specified Days
Other Names:
  • BMS-734016
  • Yervoy

Drug: Carboplatin
Specified Dose on Specified Days

Drug: Cisplatin
Specified Dose on Specified Days

Drug: Paclitaxel
Specified Dose on Specified Days

Drug: Pemetrexed
Specified Dose on Specified Days




Primary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: Up to 6 months after the last subject first treatment ]

    Part 1 - nivolumab + ipilimumab

    In all treated PD-L1 positive (≥ 1%)


  2. ORR [ Time Frame: Up to 6 months after the last subject first treatment ]

    Part 1 - nivolumab + ipilimumab

    In all treated PD-L1 negative (< 1%)


  3. Number of Patients with dose Limiting Toxicities (DLTs) [ Time Frame: 9 weeks after last subject first treatment ]

    Part 2 - nivolumab + ipilimumab + 2 cycles platinum doublet chemotherapy

    To determine DLT


  4. Number of Adverse Events (AEs) [ Time Frame: Up to 6 months after the last subject first treatment ]

    Part 2 - nivolumab + ipilimumab + 2 cycles platinum doublet chemotherapy

    Safety and Tolerability


  5. Number of Serious Adverse Events (SAEs) [ Time Frame: Up to 6 months after the last subject first treatment ]

    Part 2 - nivolumab + ipilimumab + 2 cycles platinum doublet chemotherapy

    Safety and Tolerability


  6. Number of Deaths [ Time Frame: Up to 6 months after the last subject first treatment ]

    Part 2 - nivolumab + ipilimumab + 2 cycles platinum doublet chemotherapy

    Safety and Tolerability


  7. Number of Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) [ Time Frame: Up to 6 months after the last subject first treatment ]

    Part 2 - nivolumab + ipilimumab + 2 cycles platinum doublet chemotherapy

    Safety and Tolerability



Secondary Outcome Measures :
  1. Progression free survival (PFS) [ Time Frame: 6 months after the last subject first treatment ]
    Part 1 - nivolumab + ipilimumab

  2. Overall Response Rate (ORR) [ Time Frame: 6 months after the last subject first treatment ]
    Part 1 - nivolumab + ipilimumab

  3. Overall Survival (OS) [ Time Frame: 14 months after the last subject first treatment ]
    Part 1 - nivolumab + ipilimumab

  4. PFS [ Time Frame: 6 months after the last subject first treatment ]
    Part 2 - nivolumab + ipilimumab + 2 cycles platinum doublet chemotherapy

  5. ORR [ Time Frame: 6 months after the last subject first treatment ]
    Part 2 - nivolumab + ipilimumab + 2 cycles platinum doublet chemotherapy

  6. OS [ Time Frame: 6 months after the last subject first treatment ]
    Part 2 - nivolumab + ipilimumab + 2 cycles platinum doublet chemotherapy



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

For more information regarding Bristol-Myers Squibb (BMS) Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Men and Women ≥ 18 years of age
  • Diagnosed with stage IV Non-Small Cell Lung Cancer
  • Diagnosed with recurrent stage IIIB non-small cell lung cancer and failed previous concurrent chemoradiation with no further curative options.

Exclusion Criteria:

  • Subjects with untreated CNS metastases are excluded.
  • Subjects with carcinomatous meningitis
  • Subjects with an active, known or suspected autoimmune disease.
  • Subjects with a condition requiring systemic treatment with either corticosteroids ( > 10 mg daily prednisone

equivalent) or other immunosuppressive medications within 14 days of first treatment.

  • Women who are pregnant, plan to become pregnant, and/or breastfeed during the study.

Other protocol defined inclusion/exclusion criteria could apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02659059


Locations
Show Show 32 study locations
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT02659059    
Other Study ID Numbers: CA209-568
First Posted: January 20, 2016    Key Record Dates
Last Update Posted: July 12, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Paclitaxel
Carboplatin
Nivolumab
Pemetrexed
Ipilimumab
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological
Enzyme Inhibitors
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors